A lack of correct ancillary supplies can be the difference between a clinical trial starting on time or having to delay at significant cost to the sponsor. The Covid-19 pandemic exacerbated what would already be a difficult task of sourcing and purchasing trial equipment. Ancillare CEO Joanne Santomauro explains how the situation developed and how her company stayed ahead of the curve and minimised the impact of shortages in the supply chain.
As published in Clinical Trials Insight 2021
